Clark, AJ; Kugathasan, U; Baskozos, G; Priestman, DA; Fugger, N; Lone, MA; Othman, A; ... Bennett, DL; + view all Clark, AJ; Kugathasan, U; Baskozos, G; Priestman, DA; Fugger, N; Lone, MA; Othman, A; Chu, KH; Blesneac, I; Wilson, ER; Laurà, M; Kalmar, B; Greensmith, L; Hornemann, T; Platt, FM; Reilly, MM; Bennett, DL; - view fewer (2021) An iPSC model of hereditary sensory neuropathy-1 reveals L-serine-responsive deficits in neuronal ganglioside composition and axoglial interactions. Cell Reports Medicine , 2 (7) , Article 10034. 10.1016/j.xcrm.2021.100345.

Preview

Text 1-s2.0-S2666379121001944-main.pdf - Published Version Download (5MB) | Preview

Abstract

Hereditary sensory neuropathy type 1 (HSN1) is caused by mutations in the SPTLC1 or SPTLC2 sub-units of the enzyme serine palmitoyltransferase, resulting in the production of toxic 1-deoxysphingolipid bases (DSBs). We used induced pluripotent stem cells (iPSCs) from patients with HSN1 to determine whether endogenous DSBs are neurotoxic, patho-mechanisms of toxicity and response to therapy. HSN1 iPSC-derived sensory neurons (iPSCdSNs) endogenously produce neurotoxic DSBs. Complex gangliosides, which are essential for membrane micro-domains and signaling, are reduced, and neurotrophin signaling is impaired, resulting in reduced neurite outgrowth. In HSN1 myelinating cocultures, we find a major disruption of nodal complex proteins after 8 weeks, which leads to complete myelin breakdown after 6 months. HSN1 iPSC models have, therefore, revealed that SPTLC1 mutation alters lipid metabolism, impairs the formation of complex gangliosides, and reduces axon and myelin stability. Many of these changes are prevented by L-serine supplementation, supporting its use as a rational therapy.

Download activity - last month

Export as XMLCSVJSON

Download activity - last 12 months

Export as CSVJSONXML

Downloads by country - last 12 months

Export as XMLCSVJSON

Archive Staff Only

View Item